Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.70M | -99.00K | 1.12M | 3.53M | 7.53M |
| Total Depreciation and Amortization | 535.00K | 471.00K | 454.00K | 238.00K | 415.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.26M | 685.00K | 1.85M | 1.04M | 1.98M |
| Change in Net Operating Assets | -5.63M | -3.82M | -1.70M | -10.30M | -7.05M |
| Cash from Operations | -129.00K | -2.76M | 1.73M | -5.49M | 2.88M |
| Capital Expenditure | -122.00K | 65.00K | -693.00K | -1.46M | -231.00K |
| Sale of Property, Plant, and Equipment | 1.00K | 138.00K | -5.00K | 218.00K | 50.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.09M | -2.21M | -1.69M | -7.04M | -7.04M |
| Cash from Investing | 1.97M | -2.00M | -2.39M | -8.27M | -7.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.47M | 1.33M | 374.00K | 275.00K | 658.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -121.00K | -367.00K | -50.00K | -119.00K | -- |
| Cash from Financing | 1.34M | 964.00K | 324.00K | 156.00K | 658.00K |
| Foreign Exchange rate Adjustments | 50.00K | -255.00K | 106.00K | -78.00K | -46.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.23M | -4.05M | -231.00K | -13.69M | -3.72M |